TapewireFind a company

person · Reporting owner

Nevinny Corinne H

Disclosed activity across 2 companies

Tapewire entity
113175
SEC CIK
0001182467

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
INSULET CORPPODD · Entity 3516DirectorMay 23, 2023May 24, 2023
NEUROCRINE BIOSCIENCES INCNBIX · Entity 2655DirectorMay 24, 2018May 25, 2018

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

INSULET CORP

Report date May 23, 2023 · Filed May 24, 2023

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect6,010 Reported balance After 2023-05-23 transaction · row 1
1 source row

Row 1 · 2023-05-23 · Grant · Acquired 843 · Balance 6,010

F1: Annual equity award in the form of restricted stock units ("RSUs"). These RSUs vest in full on April 30, 2024 and are settled in shares of common stock on a one-for-one basis.

Filing footnotes · ownership attribution and instrument terms

F1: Annual equity award in the form of restricted stock units ("RSUs"). These RSUs vest in full on April 30, 2024 and are settled in shares of common stock on a one-for-one basis.

NEUROCRINE BIOSCIENCES INC

Report date May 24, 2018 · Filed May 25, 2018

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Non-Qualified Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $94.64 · Expires 2028-05-24Direct12,500 Reported balance After 2018-05-24 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2018-05-24 · Grant · Acquired 12,500 · Balance 12,500

F1: Option vests in 12 equal monthly installments beginning June 24, 2018.

Filing footnotes · ownership attribution and instrument terms

F1: Option vests in 12 equal monthly installments beginning June 24, 2018.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
May 23, 2023 Filed May 24, 2023 20:13 UTC INSULET CORP PODD · Entity 3516 GrantCommon Stock 843 $0.00 $0.00
Disclosure

SEC source: 0001127602-23-016716 · form4.xml · nonDerivative · entry 1

Nevinny Corinne H · CIK 0001182467 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,010

F1 · shares: Annual equity award in the form of restricted stock units ("RSUs"). These RSUs vest in full on April 30, 2024 and are settled in shares of common stock on a one-for-one basis.

Read SEC document
May 24, 2022 Filed May 26, 2022 20:11 UTC INSULET CORP PODD · Entity 3516 GrantCommon Stock 1,009 $0.00 $0.00
Disclosure

SEC source: 0001127602-22-015766 · form4.xml · nonDerivative · entry 1

Nevinny Corinne H · CIK 0001182467 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,167

F1 · shares: Annual equity award in the form of restricted stock units ("RSUs"). These RSUs vest in full on April 30, 2023 and are settled in shares of common stock on a one-for-one basis.

Read SEC document
May 27, 2021 Filed May 28, 2021 20:11 UTC INSULET CORP PODD · Entity 3516 GrantCommon Stock 808 $0.00 $0.00
Disclosure

SEC source: 0001127602-21-018312 · form4.xml · nonDerivative · entry 1

Nevinny Corinne H · CIK 0001182467 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,158

F1 · shares: Annual equity award in the form of restricted stock units ("RSUs"). RSUs vest in full on April 30, 2022 and are settled in shares of common stock on a one-for-one basis.

Read SEC document
May 13, 2021 Filed May 14, 2021 20:06 UTC INSULET CORP PODD · Entity 3516 SaleCommon Stock 933 $231.42 $215,914.86
Disclosure

SEC source: 0001127602-21-016804 · form4.xml · nonDerivative · entry 1

Nevinny Corinne H · CIK 0001182467 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,350

F1 · price: The price reported represents the weighted average sale price of the shares sold. The shares were sold at varying prices in the range of $231.20 to $231.43. The Reporting Person hereby undertakes, upon request of the Staff of the U.S. Securities Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares sold at each separate price.

Read SEC document
May 28, 2020 Filed Jun 1, 2020 21:03 UTC INSULET CORP PODD · Entity 3516 GrantCommon Stock 1,029 $0.00 $0.00
Disclosure

SEC source: 0001127602-20-018254 · form4.xml · nonDerivative · entry 1

Nevinny Corinne H · CIK 0001182467 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,283

F1 · shares: Annual equity award in the form of restricted stock units ("RSUs"). RSUs vest in full on April 30, 2021 and are settled in shares of common stock on a one-for-one basis.

Read SEC document
May 01, 2020 Filed May 4, 2020 20:26 UTC INSULET CORP PODD · Entity 3516 SaleCommon Stock 863 $196.82 $169,855.66
Disclosure

SEC source: 0001209191-20-026778 · doc4.xml · nonDerivative · entry 2

Nevinny Corinne H · CIK 0001182467 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,254

F1 · shares: The transactions reported in this Form 4 were effected pursuant to an existing Rule 10b5-1 trading plan.

Read SEC document
April 30, 2020 Filed May 4, 2020 20:26 UTC INSULET CORP PODD · Entity 3516 SaleCommon Stock 796 $195.54 $155,649.84
Disclosure

SEC source: 0001209191-20-026778 · doc4.xml · nonDerivative · entry 1

Nevinny Corinne H · CIK 0001182467 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,117

F1 · shares: The transactions reported in this Form 4 were effected pursuant to an existing Rule 10b5-1 trading plan.

Read SEC document
May 30, 2019 Filed Jun 3, 2019 21:47 UTC INSULET CORP PODD · Entity 3516 GrantCommon Stock 1,726 $0.00 $0.00
Disclosure

SEC source: 0001127602-19-020544 · form4.xml · nonDerivative · entry 1

Nevinny Corinne H · CIK 0001182467 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,913

F1 · shares: Annual equity award in the form of restricted stock units ("RSUs"). RSUs vest in full on April 30, 2020 and are settled in shares of common stock on a one-for-one basis.

Read SEC document
January 25, 2019 Filed Jan 29, 2019 21:13 UTC INSULET CORP PODD · Entity 3516 GrantCommon Stock 3,187 $0.00 $0.00
Disclosure

SEC source: 0001127602-19-002869 · form4.xml · nonDerivative · entry 1

Nevinny Corinne H · CIK 0001182467 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,187

F1 · balance_after: The 3,187 restricted stock units vest as to one-half of the total units on January 25, 2020, one-quarter of the total units on January 25, 2021 and one-quarter of the total units on January 25, 2022 , subject to continued service as a director. Vested shares will be delivered to the reporting person as soon as practicable following a vesting date.

Read SEC document
May 24, 2018 Filed May 25, 2018 23:56 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 GrantNon-Qualified Stock Option · Derivative 12,500 $0.00 Strike: $94.64 $0.00
Disclosure

SEC source: 0001209191-18-033629 · doc4.xml · derivative · entry 1

Nevinny Corinne H · CIK 0001182467 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,500

Underlying: Common Stock · 12,500 shares

Expires 2028-05-24

F1 · derivative.exercise_date: Option vests in 12 equal monthly installments beginning June 24, 2018.

Read SEC document
May 07, 2018 Filed May 9, 2018 22:12 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 SaleCommon Stock 5,000 $83.13 $415,625.00
Disclosure

SEC source: 0001209191-18-028971 · doc4.xml · nonDerivative · entry 1

Nevinny Corinne H · CIK 0001182467 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 43,283

F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $82.42 to $83.69. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
May 02, 2018 Filed May 3, 2018 23:53 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 Exercise / conversionNon-Qualified Stock Option · Derivative 15,000 $7.05 Strike: $7.05 $105,750.00
Disclosure

SEC source: 0001209191-18-027902 · doc4.xml · derivative · entry 3

Nevinny Corinne H · CIK 0001182467 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 15,000 shares

Expires 2018-05-25

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
May 02, 2018 Filed May 3, 2018 23:53 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 Tax withholdingCommon Stock 1,320 $80.08 $105,705.60
Disclosure

SEC source: 0001209191-18-027902 · doc4.xml · nonDerivative · entry 2

Nevinny Corinne H · CIK 0001182467 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 48,283

F1 · price: The share issuance reported on Table I reflects shares issued upon the exercise of options granted on May 25, 2011, which, if unexercised would have expired on May 25, 2018. The option exercises are reported on Table II. These option exercises were pursuant to a net issuance arrangement effected under the Issuer's 2003 Equity Incentive Plan, as amended. The number of shares issued pursuant to the net issuance arrangement was calculated as follows: the option exercise price ($7.05) was subtracted from the May 02, 2018 market close price ($80.08), and this net amount ($73.03) was then multiplied by the number of options (15,000), with the resulting amount then divided by the market close price to result in a net issuance of 13,680 shares to the optionee. The 1,320 shares underlying the remaining portion of the options are not available for re-issuance, and no shares were sold into the market as a part of the exercise in connection with a net issuance program.

Read SEC document
May 02, 2018 Filed May 3, 2018 23:53 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 Exercise / conversionCommon Stock 15,000 $7.05 $105,750.00
Disclosure

SEC source: 0001209191-18-027902 · doc4.xml · nonDerivative · entry 1

Nevinny Corinne H · CIK 0001182467 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 49,603

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The share issuance reported on Table I reflects shares issued upon the exercise of options granted on May 25, 2011, which, if unexercised would have expired on May 25, 2018. The option exercises are reported on Table II. These option exercises were pursuant to a net issuance arrangement effected under the Issuer's 2003 Equity Incentive Plan, as amended. The number of shares issued pursuant to the net issuance arrangement was calculated as follows: the option exercise price ($7.05) was subtracted from the May 02, 2018 market close price ($80.08), and this net amount ($73.03) was then multiplied by the number of options (15,000), with the resulting amount then divided by the market close price to result in a net issuance of 13,680 shares to the optionee. The 1,320 shares underlying the remaining portion of the options are not available for re-issuance, and no shares were sold into the market as a part of the exercise in connection with a net issuance program.

Read SEC document
May 22, 2017 Filed Jun 8, 2017 22:32 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 GrantStock Option · Derivative 15,000 $0.00 Strike: $53.64 $0.00
Disclosure

SEC source: 0001209191-17-038632 · doc4.xml · derivative · entry 1

Nevinny Corinne H · CIK 0001182467 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2027-05-22

F1 · derivative.exercise_date: Option vests in 12 equal monthly installments beginning June 22, 2017.

Read SEC document
May 05, 2017 Filed May 9, 2017 00:22 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 SaleCommon Stock 5,000 $53.98 $269,900.00
Disclosure

SEC source: 0001209191-17-030722 · doc4.xml · nonDerivative · entry 1

Nevinny Corinne H · CIK 0001182467 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 34,603

F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $53.55 to $54.37. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
May 03, 2017 Filed May 5, 2017 17:26 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 Exercise / conversionNon-Qualified Stock Option · Derivative 15,000 $0.00 Strike: $3.40 $0.00
Disclosure

SEC source: 0001209191-17-030238 · doc4.xml · derivative · entry 3

Nevinny Corinne H · CIK 0001182467 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 15,000 shares

Expires 2017-05-25

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
May 03, 2017 Filed May 5, 2017 17:26 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 Tax withholdingCommon Stock 952 $53.37 $50,808.24
Disclosure

SEC source: 0001209191-17-030238 · doc4.xml · nonDerivative · entry 2

Nevinny Corinne H · CIK 0001182467 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 39,603

F1 · price: The share issuance reported on Table I reflects shares issued upon the exercise of options granted on May 25, 2010, which, if unexercised would have expired on May 25, 2017. The option exercises are reported on Table II. These option exercises were pursuant to a net issuance arrangement effected under the issuer's Equity Incentive Plan. The number of shares issued pursuant to the net issuance arrangement was calculated as follows: the option exercise price ($3.40) was subtracted from the May 03, 2017 market close price ($53.57), and this net amount ($50.17) was then multiplied by the number of options (15,000), with the resulting amount then divided by the market close price to result in a net issuance of 14,048 shares to the optionee. The 952 shares underlying the remaining portion of the options are not available for re-issuance, and no shares were sold into the market as a part of the exercise in connection with a net issuance program.

Read SEC document
May 03, 2017 Filed May 5, 2017 17:26 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 Exercise / conversionCommon Stock 15,000 $3.40 $51,000.00
Disclosure

SEC source: 0001209191-17-030238 · doc4.xml · nonDerivative · entry 1

Nevinny Corinne H · CIK 0001182467 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,555

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The share issuance reported on Table I reflects shares issued upon the exercise of options granted on May 25, 2010, which, if unexercised would have expired on May 25, 2017. The option exercises are reported on Table II. These option exercises were pursuant to a net issuance arrangement effected under the issuer's Equity Incentive Plan. The number of shares issued pursuant to the net issuance arrangement was calculated as follows: the option exercise price ($3.40) was subtracted from the May 03, 2017 market close price ($53.57), and this net amount ($50.17) was then multiplied by the number of options (15,000), with the resulting amount then divided by the market close price to result in a net issuance of 14,048 shares to the optionee. The 952 shares underlying the remaining portion of the options are not available for re-issuance, and no shares were sold into the market as a part of the exercise in connection with a net issuance program.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.